PATENT CLAIM ANALYSIS

Application Number: 16211564
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "218100"]

Abstract:
The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4 linked to the N-terminal of HBsAg.

Claim (Index 10):
A tetravalent dengue vaccine comprising a virus like particle (VLP) comprising:\n a) a recombinant polypeptide comprising an EDIII domain of each of Dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4, linked to N-terminal of an HBsAg polypeptide, as depicted below: EDIII-1 - - - EDIII-3 - - - EDIII-4 - - - EDIII-2 - - - HBsAg; wherein the dotted line is a linker; and wherein the amino acid sequence of the EDIII domains of each of Dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4 is SEQ ID NO's 1, 2, 3 and 4, respectively; and b) 4 units of an HBsAg polypeptide.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 1.19231
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15506379', '15320033', '15523899', '14130839', '14921701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7588462929628661
- 35 USC 102 Novelty (BERT): 0.6927070879008883
- Combined Prediction Score: 0.7522323724566683
- Mean Citation Score: 440.981272
- Max Citation Score: 758.35583
- Similarity Product: 698.1155251472667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test